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A 2 Epidemiology, Natural History, Risk Factors
A 2.1 Introduction to Epidemiology
The management of the patient with peripheral arterial disease (PAD) has to be planned in the
context of the epidemiology of the disease and , in particular, the apparent risk factors or markers
predicting spontaneous deterioration. It is also necessary to know the magnitude of the problem
together with the likely outcome in patients with differing severity of PAD to analyze outcome
measures and to assess the socioeconomic impact of the disease. A detailed search of all the rele-
vant publications was performed for this chapter. The resulting full analysis of the data has
been published separately in Seminars in Vascular Surgery.l A full list of references and
complete tables of data also can be found in that publication. Those tables are the basis
for the summary figures and diagrams reproduced in this document,
A 2.2 Intermittent Claudication
A 2.2.1 The Problem of Defining Intermittent Claudication
Intermittent claudication (IC) is usually diagnosed by a history of leg pain on exercise that is
relieved by rest . Several questionnaires have been developed for epidemiological use. Other
diagnostic methods include interview, clinical examination, and noninvasive tests. In looking at
methods for identifying IC in the population, it must be remembered that it is merely a symp-
rom of PAD and that the measurement of symptoms is notoriously difficult . A patient with
quite severe PAD may not have the symptom of IC because some other condition limits exer-
cise. Likewise, patients with very mild PAD may have symptoms of IC if they are very active.
Questionnaires
The WHO/Rose Questionnaire has been the most widely used cardiovascular questionnaire for
the identification of patients with Ie. It was designed in 1962 by Rose,2 was subsequently
adopted by the WHO, and has been widely used to estimate the prevalence of intermittent clau-
dication.I In one survey in a large population in France, this questionnaire was shown to be high-
ly specific (9 9 .8%) in excluding healthy individuals but only moderatel y sensitive (67.5%) in
detecting those with claudication compared with physicians' assessments of symptoms (Table 1).3
In other words, there were only 0.2% false; false positives are questionnaire-positive individuals
who were not patie nts with intermittent claudication) but 32.5% false negatives (false negatives
are patients with intermittent claudication who were questionnaire negative). The classification
was extended in 1985 to include "possible claudicants" (ie, those patients with exercise leg pain
that is not present at rest, but who are not otherwise fully concordant with the Rose criteria) to
try to improve the questionnaire's sensitivity, but at the expense of a slight decrease in specificity.t
Table 1. Diagnostic perform ance o f various techniques for defining IC/PAD
WH O/Rose questionnaire
Rose, 19 622
Richard et al, 19 723
Isacsson, 197228
Criqui er al, 198 54
Ed inburgh questionnaire
Leng & Fowkes, 19925
WHO/Rose questionnaire {lIId ABPI c 0.9
Criqui et ai, 19854
Ogren et ai, 199 329
·Probable claudication **Possible claudication
Sm sitivity (%)
92
67 .5
30
9"
20··
91
71.2
15
Diagn ostic per(immmce
Specificity(%)
100
99.8
98
99*
95.9**
99
91.3
98
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The Edinburgh Claudication Questionnaire is designed to be self-administered.f The main dif-
ferences compared with the WHO/Rose questionnaire are i) patients answering negatively to
leg pain or discomfort when walking do not continue with the questionnaire and ii) the patient
is asked to mark the place(s) of the pain on a diagram. This questionnaire was validated in a
study of approximately 300 patients older than 55 years who consulted their general practition-
er. When compared with the independent assessment of two blinded clinicians, the question-
naire showed a sensitivity of 91%and a specificity of 99% for the diagnosis of LC,5 Table 1
shows that the principal problem with questionnaires seems to be that they are too rigorous
(low sensitivity), therefore underestimating the true prevalence of IC. Furthermore, the inaccu-
racy of any questionnaire probably varies according to the age, occupation, and other character-
istics of the population to which it is applied. The conclusion is that one must be wary of any
epidemiological data based solely on questionnaires.
Clinical assessment
Although leg pain associated with exercise and relieved by rest is suggestive ofIC, it is not suffi-
cient on its own for a definite diagnosis. A detailed history taken by a clinician will help to iden-
tify those patients whose leg pain on exercise is attributable to another cause, for example, nerve
root compression or severe venous insufficiency. However, the addition of a clinical examination
does not necessarily eliminate the errors found on questionnaires alone. False-positive rates of
up to 44% and false-negative rates of up to 19%have been reported after verification by nonin-
vasive tests.P-?
The single most important part of the physical examination to confirm a diagnosis ofIC is pal-
pation of the patient's peripheral pulses. It must be remembered, however, that an absent pulse
may be attributable to causes other than arterial disease. A prospective study of 1,000 children
aged between 1 and 10 years were examined for the presence of dorsalis pedis and posterior tib-
ial pulses.f The posterior tibial pulse was invariably present, whereas the dorsalis pedis was con-
genitally absent in 12% of the children. In addition, the prevalence of absence of dorsalis pedis
was three times as high in white children compared with black children. A further study by
Ludbrook et al9 examined pulses in patients admitted to hospital for noncardiovascular causes.
In the 0- to 19-year age-group, the posterior tibial and dorsalis pedis arteries were absent in
0.2% and 8.7% of patients, respectively?
At least one pulse is not detected in approximately 10% of the adult population when the
femoral, posterior tibial, and dorsalis pedis arteries are palpated. to However, 3% of these were
asymptomatic (Figure 2). At least part of the problem is observer error in detecting pulses.
Similar variability or reproducibility in the detection of peripheral pulses was found in two stud-
ies in hospital paticnts.P.U However, the authors of these two studies reached very different
conclusions. In the first, they found that the agreement between the observers improved during
the study and reached "satisfactory levels,"? and in the second, the authors thought that there
was "very great observer error," which did not diminish during the study. 11
It has been suggested that, for most epidemiological research, palpation of the peripheral pulses
is probably too insensitive a measure of PAD. However, the situation in general practice appears
to be different. The authors of a large general practice study in Holland, in 2,455 patients with
leg complaints, concluded that palpation of both foot pulses is the key procedure for the clinical
diagnosis of PAD,12 This enables the general practitioner to exclude the diagnosis in many
patients with a high degree of certainty, establish the diagnosis in a small group of patients, and
identify a limited group who require further noninvasive testing. Figure 2 shows the interrela-
tions between intermittent claudication, pulselessness, and ankle:brachial pressure index (ABPI)
in 666 men and women.
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Figure 2. Interrelation between intermittent claudication, pulselessness,and ABPI in 666 men and
WOmen. 10
Intermittent
Claudication
n =25
46
Oneor more
absentankle pulse
n::: 70
A8PI < 0.9
n::: 95
Ankle: brachial pressure index
For epidemiology purposes, the most useful noninvasive test is the ABPI, The Doppler ankle
systolic pressure has been shown to correlate closely with direct intraarterial recordings. 13,14 The
Doppler probe is also easier to use than other techniques, such as pleth ysmography.l5,16 The
Doppler is very inexpensive ; the measurements are rapid, painless, and can be well
standardized.U' Although it has been suggested that strain-gauge plethysmography is more accu-
rate than the Doppler for ABPI, it is more difficult to use, and at least one study suggests that it
is no more reproducible.l? It is generally recognized that the Doppler systolic pressure. may be
inaccurate if the artery is not compressible, as occurs, for instance, in some. diabetic patients. In
addition, the use of ABPI measurement de.pends on the brachial pressure being a true central
systolic pressure. This may not be the case in patients with subclavian artery stenosis , which is
most frequent in diabetic patients and patients with CLI.
The variability in measuring ankle pressure has been examined in several srudies.lO,1 8,19,20,21 In
one study,10 ankle systolic pressure was found to vary in a way similar to arm systolic pressure,
whereas "good reproducibility" was found in another smdy18 when two successive measure-
ments were made . Baker and Dix19 found that repeated measurements produced an average
range of 0.18 in the ABPI, and Carter22 found that 95%of repeat ABPI were within 9% of the
average. 22 The variability in both ankle systolic pressure and ABPI measured on different occa-
sions by different observers appears to have only a marginal effect on between-subject
variability.-!
It has been suggested that a resting ABPI of 0,90 is up to 95% sensitive in detecting angiogram-
positive disease and almost 100%specific in identifying apparently healthy individuals.20,22,23,24,25,26
Although specificity in the normal population is close to 100%, in patients with, for instance, dia-
betes, the specificity will be less. Most of these studies have used selected, symptomatic, hospital
patients and controls who were considered healthy because they were young or had no signs or
symptoms . Individuals with vascular disease who had an angiographically normal limb also were
used as controls. Thus, it is not known how ABPI in the general population would correlate with
angiographic findings in PAD. However, results among those with severe disease likely would be
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Figure 3: Incidence of LC in men at different ages in five population studies.
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similar to those found in hospital patients. The Edinburgh Artery Study found an association
between ABPI and disease severity in the general population.I? Table 1 compares the sensitivity
and specificity of the various methods that have been used to study the incidence and prevalence
ofIC and PAD. It should always be remembered that the ABPI, or indeed the palpation of
pulses, assesses PAD, which is not necessarily synonymous with IC.
A 2.2.2 Incidence of Intermittent Claudication
Knowledge of the incidence and prevalence of IC is essential tor socioeconomic calculations and
for health care planning On both a regional and a national basis. Estimates of the incidence of
IC or PAD in a population are subject to a number of errors. Only a minority of patients with
demonstrable PAD complain of symptoms of IC, whereas many patients with IC are elderly and
consider that their symptoms are part of growing old; therefore, they do not seek medical
advice. Patients' occupations and habitats greatly influence the appearance of symptoms. Thus,
the proportion who consult their general practitioner varies from 10% in the inner city30 to 50%
in rural communities.U Because most of the patients who consult their physicians are not
referred to a specialist, incidences based on hospital referrals are grossly underestimated. 32
Although questionnaires enable a wider and less selected population to be sampled, as already
stated, they tend to overdiagnose arterial diseasc. 30,31,33,34,35,36 Studies that focus on working
populations also can result in bias, for two reasons: First, the presence of the symptoms may be
related to the nature of the work. Thus, IC has been found to be more common among agricul-
tural workers than in civil servants. Second, individuals incapacitated by PAD may be automati-
cally excluded by the nature of their work. Figure 3 shows the incidence of Ie in men at diner-
ent ages in various studies, with an obvious wide variation in the absolute figures that can only
partly be explained by differences in methodology It is interesting, however, that the two stud-
ies of unselected populations that also used ABPI measurements report the lowest incidence of
I'C. Within each study, there is a general pattern of a gradual increase in incidence up to tile age
of at least 60 years. Figure 4 shows the weighted mean incidence of Ie found in five large pop-
ulation-based studies.
A 2.2.3 Prevalence of Intermittent Claudication
Many more studies have been done regarding the prevalence rather than the incidence of LC,
However, prevalence rates also differ depending on the study population and the diagnostic
methods used. Even when the same diagnostic technique is used, this can result in different
prevalence rates, depending on the age, sex, and geographic location of tile population studied.
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'Figure 4: Weighted mean incidence of intermittent claudication from five large population-based studies.
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Table 2: Prevalence of IC in men in large population studies
Sttldy Location Population sample Age (yrs) Prevalence (%)
Hughson et al, 197831 Oxfordshire 1,716 45-69 2.2
De Backer er al, 197938 Belgium 8,252 40-49 0.8
50-59 2.3
Reunanen er al, 198233 Finland 5,738 30-39 0.6
40-49 1.9
50-59 4.6
Fowkes ct aI, 1991 42 Edinburgh, Scotland 1,592 55-74 4.5*
Stoffers er al, 199139 Holland 3,654 men & women 45-54 0.6
55-64 2.5
67-74 8.8
Smith et aI, 1991 40 Scotland 10,042 men & women 40-59 1.1
Novo et al, 19924 1 Palermo 1,558 men & women 40-49 4.7
50-59 9.2
*Overall prevalence for men and women aged 55-74 years: 4.5%.
Thus, reported prevalence rates for Ie using the Rose questionnaire vary from 0.4% to 14.4%.32
Table 2 contains the larger studies using methodology that is relatively reliable. Figure 5 sum-
marizes these data.
In the Limburg study, 3,654 individuals aged 40 to 79 years were examined by their general
practitioners, and the diagnosis ofIC was based on medical history, clinical examination, and
data from the patient's history.-? Independently of the general practice, the practice assistants
assessed ABPI using a pocket Doppler device and a mercury sphygmomanometer. An ABPI of
less than 0.95, measured twice within a week, was considered evidence of PAD. An ABPI of less
than 0.95 probably overestimates PAD. The prevalence of PAD in this study ranged from 1.4%
for that diagnosed using the strict Rose criteria to 1.8% for that diagnosed by general practition-
ers and 6.1 %when an ABPI ofless than 0.95 was used. Similar figures were obtained from the
Edinburgh .Artery Study and the Scottish Heart Health Study, using similar methodologies.40,42
The latter was one of dle largest studies, over 10,000 subjects, to use clinical examination for
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Figure 5: Weighted mean prevalence of intermittent claudication in large population-based studies.
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diagnosing IC. The Finnish study was also similar in magnitude and methodology as were the
results.V The Oxford study was unusual in that questionnaire-positive subjects also had postex-
ercise as well as resting pressure measurements.s!
In the larger, more reliable studies, there is a reasonable consistency in the results; at around the
age of 60 years, the prevalence ofK' in men is 3% to 6%. Figure 6 shows these results graphical-
ly, giving a rough idea of the changing prevalence with age in men. Although the prevalence in
men is always greater than that for women at all ages, no clear pattern emerges of any changes
in the ratio with age, with ratios varying from a little over 1 to over 8 in one study.
Prevalence of asymptomatic disease
The prevalence of asymptomatic disease can be estimated only by using noninvasive techniques.
The most widely used noninvasive test to detect asymptomatic disease has been the measure-
ment of ankle systolic pressures. 10,43,44 The Basle studytf used pulse waveforms detected by
oscillography, and a USA study also included a reactive hyperemia test.46 Noninvasive diagnostic
tests have not been widely used in epidemiological surveys of PAD. The prevalence of asympto-
matic disease in various studies ranges from 0.9% to 22%, with the ratio of symptomatic to
asymptomatic disease in individual studies ranging hom 1:0.9 to 1:6.0.4,10,38,42,43,45,47,48,49,50
The detected prevalence of asymptomatic PAD largely depends on the measurement technique
used. This is well illustrated in Hiatt et ai's careful study in Califomia.U A resting ABPI of less
than 0.9 is believed to be associated with a 50% or greater vessel stenosis and could serve as an
arbitrary definition of PAD. Detailed analysis of the available data suggests that for every patient
with IC there are probably another three with asymptomatic disease causing a 50% or greater
stenosis of the arteries supplying the legs.
A 2.2.4 Risk Factors for Developing Intermittent Claudication
The risk factors for developing PAD are similar to those for other atherosclerotic diseases. The
influence of age and sex in the incidence and prevalence of LC has already been considered. A
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Figure 6: Prevalence of IC in men in various studies.
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number of studies have looked at other classical risk factors , such as diabetes, hypertension, lipid
abnormalities, and smoking, as well as som e more recently identified associations, such as plasma
fibrinogen levels, impaired glucose tolerance, and hyperhomocysteinemia.
Diabetes mellitus and impairedglucose tolerance
Many studies have shown an association between diabetes mellitus and the development of
PAD.34,44,52,53,54,55,56,57,58,59 Overall, IC seems to be about twice as common amongst diabetic
patients as among nondiabetic patients. Over the last decade, mounting evidence has suggested
that insulin resistance p lays a key role in the so-called metabo lic synd rome, which is charac ter-
ized by the coincidence of obesity, non-insulin-dependent diabetes mellitus, hyperinsulinemia,
hyperlipidemia, hypertension, hyperuricemia, and cardi ovascular disease.s?
Smoking
The relationship between smoking and PAD has been recognized since 1911, when Erb 61
reported that IC was 3 times more common among smokers than among nonsmokers.
Interventions to decrease or eliminate cigarette smoking have therefore long been advocated for
patients with Ie. It has been suggested that the association between smoking and PAD may be
even stro nge r than that between smo king and coronary artery disease (CAD ).44,56,59,62 In the
Framingham stu dy, the risk at all ages was almost double for PAD compared with CAD .34 All
epidemiological studies of PAD have confirmed that cigarette smoking is a strong risk factor for
the development ofI e.10,31,33,34,43,53,55,56,63 In addition, a diagnosis of PAD is made up to a
decade earl ier in sm okers than in nonsl110kers.44 ,64,65
The severity of PAD tends to increase with the number of cigarettes smoked.66,67,68,69,70,71
Cigarette smoking increased the risk of IC in both sexes, and heavy smokers had a fourfold risk
of devel oping IC.34 It has been reported that smoking cessation is associated with a rapid
decline in the incidence of IC and that the risk of IC for ex-smokers 1 year after quitting is
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approximately the same as that for nonsmokers.69,70 However, this is at variance with the results
from the Edinburgh study, which found that the relative risk of K: was 3.7 in smokers com-
pared with 3.0 in ex-smokers (discontinuation of smoking for more than 5 years).44
Hypertension
The Framingham study has provided the most convincing epidemiological evidence of a link
between hypertension and PAD.34,53,55,56 Kannel and McGee 34 showed that hypertension car-
ried a 2.S-fold age-adjusted risk in men and a 3.9-fold age-adjusted risk in women. This is also
suggested by the Edinburghv' and the Basle52 studies but not by the Whitehall 72 and the
Finnish33 studies, which found no association between PAD and hypertension. The discrepancy
between these results may in part be due to the complex link between hypertension and IC.
Both are associated with PAD, but hypertension is probably both a cause and an effect of ather-
osclerosis. Finally, hypertension may to some degree delay the onset of symptoms of IC a
patient with PAD by elevating the central perfusion pressure; it is not uncommon for a hyper-
tensive patient to develop IC when high blood pressure is discovered and treated.
Hematologic factors
Hyperlipidemia
There is conflicting evidence regarding the relationship between hyperlipidemia and PAD. In
the Framingham study, a fasting cholesterolleve1 greater than 270 mgjdL (7 mmoljL) was
associated with a doubling of the incidence ofIC. It appears that the ratio of total to high-den-
sity lipoprotein (HDL) cholesterol is the best predictor of occurrence of arterial disease.Zf
Although some studies have also shown that total cholesterol is a powerful independent risk fac-
tor for PAD,34,67 others have failed to confirm this association. 31,47,48,63,74,75 It has been sug-
gested that cigarette smoking may enhance the effect of hypercholesterolemia. There is evidence
that treatment of hyperlipidemia reduces both the progression of PAD and the incidence of
IC,76,77 An association between PAD and hypertriglyceridemia has also been reported, but the
strength of this association is unclear.l 0,31,33,34,43,63 Hypertriglyceridemia, however, has been
shown to be associated with the progression and systemic complications of PAD,78 Recently,
Cheng/? has shown that lipoprotein (a) (Lp[a]) is a significant independent risk factor for PAD.
Fibrinogen
An increased plasma level of fibrinogen has been associated with PAD in several studies, and
other studies have established the role of high fibrinogen levels as a thrombotic risk.31,80,81
Hyperhomocysteinemia
The incidence of hyperhomocysteinemia is as high as 60% in the vascular population, compared
with 1% in the general population.82,83 It is reported that hyperhomocysteinernia was detected
in 28% to 30% of patients with premature PAD.84,85 The suggestion that hyperhomocysteinemia
may be an independent risk factor for atherosclerosis has now been substantiated by several
studies.86,87,88 It may be a stronger risk factor for PAD than CAD. A meta-analysis of studies
concluded that the odds ratios for CAD were 1.6 and 1.8 in men and women, respectively,
compared with 6.8 for PAD.89 It also suggested that hyperhomocysteinemia may account for
10% of the population risk for coronary artery disease.
Hypercoaguability
Raised hematocrit levels have been found in patients with IC and have been found to be predic-
tors of future graft occIusion.90,91,92 However, this increase may well be attributable to an asso-
ciation with smoking. In the Framingham study, an elevated hematocrit was not associated with
a greater risk of IC.34 In one study, Ray et al93 showed that the prevalence ofhypercoaguabiIity
in patients with stable claudication was 25%, compared with 11%in the general population. This
increased to 40% in those patients requiring vascular intervention.
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Figure 7: Estimated probability of a 65-year-old man developing IC with a specific blood pressure
and cholesterol level and with, or without, diabetes, based on a 26-year data from the Framingham
study (Kannel and McGee, 1985 34 ) .
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Coexisting risk factors
The coexistence of at least some of the above risk factors increases the risk of PAD at least addi-
tively in the lower limbs. When cigarette smoking, diabetes mellitus, and systolic hypertension
were considered in the Basle study, the relative risk increased from 2.3 to 3.3 and 6.3 in those
individuals with one, two, or three risk factors, respcctively.H The Framingham study has found
similar results. 55 In particular, inclusion of cigarette smoking dramatically escalates the risk of IC
when combined with any other risk factors (Figure 7).
Protective factors
Inevitably, the absence of a risk factor is protective. However, other positive protective factors
for the development of IC have also been identified, including moderate alcohol intake95 and a
history of regular physical activity.96
Genetic risk
Although a positive family history has been definitely linked with coronary heart disease,
increasing the risk by 1.5- to 2-told,97 and stroke,SO,98 it has not been confirmed as a significant
risk factor for PAD. Both the Nurses' Health Study and the Framingham Offspring Study found
that a family history of CAD was an independent risk factor for CAD in women,99,lOO The
Danish Twin Concordance study found that that CAD was higher in monozygotic twins com-
pared with dizygotic twins.I''! An interesting prospective study by Marenberg et all DO looked at
21,000 twins. The study concluded that a family history of early death of coronary heart disease
is associated with an increased risk of death of the disease and that at least part of this risk was
attributable to a genetic element. l 02
A 2.2.5 Summary: Risk Factors for Developing Symptomatic PAD
Figure 8 summarizes the range of odds ratios for different risk factors. Excluding unavoidable
factors, the most important risk factors for developing symptomatic PAD are diabetes and smok-
ing, with odds ratios of approximately 2 to 3, Hypertension and lipid abnormalities are signifi-
cantly less important, and the evidence regarding their influence is more controversial.
A 2.3 Coexisting Vascular Diseases
Because PAD, CAD, and cerebrovascular disease (CVD) are all manifestations of atherosclerosis,
it is not surprising that the three conditions commonly occur together. The extent of coexisting
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Figure 8: Range of odds ratios for risk factors for developing intermittent claudication.
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cardiovascular disease must be appreciated to ensure that the physician treating IC will treat it in
a true context. Studies on the prevalence of CAD in patients with IC shows that history, clinical
examination, and electrocardiography typically indicate the presence of CAD in 40% to 60% of
such patients, although this may be asymptomatic if exercise is severely limited by claudica-
tion.31,55,103,104,105,106,107,108,109,110,l11,112,113,114,115,116
As with asymptomatic PAD, the diagnosis of CAD depends on the sensitivity of the methods
used. In one study, in which coronary angiograms were performed, the prevalence was as high
as 90%.115 All patients presenting to the Cleveland Clinic from 1978 to 1981 for elective
peripheral vascular surgery had cardiac catheterization to determine whether prophylactic treat-
ment of severe CAD could improve their long-term survival. Only 10% of the 381 patients pre-
senting with IC had normal coronary arteries on angiography, whereas 28% had severe three-
vessel disease that merited revascularization or was already inoperable. The converse is also true:
among individuals with CAD, the prevalence of PAD is higher than in non-CAD individu-
als.33,55 The relative risk ofIC among Finnish men and women with angina pectoris compared
with controls was 7.2 and 3.9, respectivelyV Aronow and Ahn 1l2 found that 33% of CAD
patients also had PAD. In the Cardiovascular Health Study, ABPI was closely correlated to the
number of patients with myocardial infarction (MI), angina, and congestive heart disease
(Figure 9) ,117
The link between PAD and CVD seems to be weaker than that with CAD. Although approxi-
mately half of all patients with IC have CAD detectable by simple clinical techniques, a much
lower proportion have demonstrable CVD.31,94,l12,lJ8 By duplex examination, carotid disease
has been found in 26% to 50% of patients with IC. Jl 9,120,121,l22 Most of these patients will have
a history of cerebral events or a carotid bruit and seem to be at increased risk of further
events,123 Aronow and Ahn 11 2 found that 33% of patients with CVD also had PAD. There is
very little reliable information on the overlap between significant arterial disease in the three cir-
culations: leg, heart, and brain. Most studies have concentrated on one area only and recorded
only superficially, if at all, the coexistence of significant arterial disease elsewhere. The large
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Figure 9: Number and percentage of patients with cardiovascular disease in subgroups with
decreasing ABPI index (Newman et aPl?).
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CAPRIE study of almost 20,000 patients is an example of this, in which the presence or absence
of claudication in the patients enrolled after MI was based on a single question. 62 The other
problem with the CAPRIE study, from an epidemiological point of view, is that the sizes of
three populations of patients with PAD, recent MI, or recent cerebrovascular accident enrolled
in the CAPRIE study were kept artificially similar by the protocol.
A more realistic picture of the overlap between PAD, CAD, and CVD is probably given by
Aronow and AIm's prospective study in 1,886 patients aged older than 62 years.1l 2 CAD, PAD,
and CVD (diagnosed by clinical history or electrocardiograph [ECG]) were all more prevalent
among men than women. Only 37% of these patients had no clinical evidence of PAD, CAD, or
CVD. Figure 10 illustrates the overlap between PAD, CAD, and CVD in these two studies. The
evidence available from all of the relevant studies suggests that approximately 60% of patients
with PAD will have significant disease in the cardiac or cerebral circulation, and approximately
40% of patients with coronary disease or significant cerebral circulatory disease will also have
PAD.
A 2.4 Fate of Patients With Peripheral Arterial Disease
A 2.4.1 Fate of Local Disease in the Legs
Intermittent claudication can progress in four different ways:
1. Improvement or stabilization
2. Worsening claudication not requiring intervention
3. A need for intervention such as surgical revascularization or angioplasry
4. A need for amputation
Worsening claudication
Although PAD is progressive in the pathological sense, its clinical course is surprisingly benign
in most cases.124 Large population studies provide the most reliable figures. These include the
816 A2 Epidemiology, Natural History, Risk Factors
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Figure 10: Overlap between PAD, CAD, and CVD in 1,886 patients aged >62 years, 37%ofwhom
had no CAD, CVD , or PAD (adapted from Aronow & Ahnttz and CAPRIE62).
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Basle study findings regarding the course of PAD, which are probably typical. This study docu-
mented angiographic progression of the disease in 63% of patients 5 years after the initial diag-
nosis.94 However, of those who had survived for 5 years after the diagnosis, 66% still had no
limiting Ie. Hospital-based series , even if essentially nonsurgical, tend to identify patients with
IC who have more severe disease or whose symptoms are progressing. A recent multinational
study, which recruited patients predominately from nonsurgical hospital clinics, showed that 6%
deteriorated in terms of walking distance over the first year.111 All of the evidence over the last
40 years since the classic study by Bloorl25 has not materially altered the impression that only
about a quarter of patients with IC will ever significantly deteriorate. This symptomatic stabiliza-
tion may be due to the development of collaterals, metabolic adaptation of ischemic muscle by
an increase in aerobic enzyme content and capillary density, or the patient altering his or her
gait to favor nonischemic muscle groups. The conditions of the remaining 25% of patients with
IC deteriorate; this is most frequent during tile first year after diagnosis (7%-9%) compared with
2% to 3% per annum thereafter. 125,126
There is a wide variation in different series in the proportion of patients with IC who ultimately
require intervention, from 3% 127 to 22%,100 which depends largely on the type of claudicant
enrolled in the study. The lower figures are likely to be a truer reflection of what happens to all
patients with IC, because the higher figures are mostly from centers to which more severe cases
have been referred. Bloor's reported major amputation rates of7% over 5 years and 12% over 10
years have been supported by other studies that also looked at selected populations several
decades ago. 103,I04,I05 However, two more recent reviews also highlight that major amputation
is a relatively rare outcome of claudication, with only 1% to 3.3%of patients with IC needing
major amputation over a 5-year period.127,128
This is likely to reflect an increase in successful limb salvage procedures rather than a change in
tile local progression of tile disease. The Basle and Framingham studies, which are the two
large-scale studies that have looked at unselected patients, found that fewer than 2% of PAD
patients required major amputation.57,73 In summary, the existing data suggest that only one
fourth of all patients with IC deteriorate progressively, and with an intervention rate of approxi-
mately 5%, only 1% or 2% of all patients with IC will ever need a major amputation. Although
amputation is the major fear of patients informed that they have circulatory disease of tile legs,
they can rest assured that this is an unlikely outcome.
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Figure II: Range of odds ratios for risk factors for the progression of local disease in the legs.
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A 2.4.2 Risks Factors for the Progression of Local Disease in the Leg
Primary risk factors for vascular disease in general tend to be only weak. secondary risk factors in
patients with IC. Figure 11 summarizes some of the studies that have looked at the magnitude
of the risk for the progression of local disease with various risk factors.
Smoking
Smoking is the most important risk factor that can be influenced. Cronenwett et al\.29 found
that patients with LC who had smoked at least 40 pack-years required reconstructive vascubr
surgery over three times more frequently than those who had smoked less. The most extreme.
example is the study by Juergens et al,130 who reported a major amputation rate of 11% in
patients with IC who smoked compared with no major amputations in nonsmokers.
Diabetes
PAD in patients with diabetes is more aggressive, with early large vessel involvement coupled
with microangiopathy. McDaniel and Cronenwettt-f showed that patients with I'C and diabetes
had a 35% risk of sudden ischemia and a 21% risk of major amputation, compared with 19% and
3%, respectively, in nondiabetic patients. Two other studies have also found increased major
amputation rates in patients with IC and diabetes, 131,132 Similar results were found by
Dorrnandy and Murray and [elnes et al.ll 1,126
ABPI
In a prospective trial in nearly 2,000 patients with IC whose entry characteristics were analyzed
to look for predictors of deterioration of PAD (eg, need for arterial surgery or major amputa-
tion), the most significant predictor was an ABPlless than 0.5. 111 This carried a relative haz-
ard ratio of 2.3, a finding similar to that of [elnes et alp6 who found that a low ABPl was
associated with a relative risk of 2.4 for local progression. Over the 6.S-year follow-up in this
study, no major amputations were required in patients with an initial ankle pressure greater
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than 70 mrn Hg, although the proportion of patients with diabetes was unusually small
(5.4%).126 Several studies have indicated that in those patients with IC in the lowest strata of
ankle pressure (ie, 40-60 rnm Hg), the risk of progression to severe ischemia or actual limb loss
was 8.5% per annum,126,133,134,135 whereas one of the studies showed a clear stepwise correla-
tion between outcome and decreasing ankle pressure. 126 There is a suggestion that claudication
has a more benign course in women. In most of the large population studies of prevalence,
there was a male.female ratio of approximately 2:1 for patients with IC, compared with ratios of
3:1 to 13:1 in series studying the disease at a later stage. 36,103,107,125,131,132 Dormandy and
Murraylll found that men had a relative risk of 1.66 for deterioration of leg ischemia compared
with women.
Hypertension
Although Ielnes et a]126 noted that the risk of deterioration was related to systemic arterial pres-
sure, the study by Dormandy and Murray.U! which included patients on antihypertensive med-
ication, and which performed a multivariate analysis to correct for the presence of other risk fac-
tors, found that hypertension did not influence the local progression of PAD,
A 2.5 Progression of Systemic Atherosclerosis
The evidence for coexisting arterial disease in patients with PAD has already been reviewed.
Patients with either asymptomatic or symptomatic PAD generally have widespread arterial dis-
ease and therefore have a significantly increased risk of stroke, MI, and cardiovascular death.
PAD should therefore be viewed as a sign of potentially diffuse and significant arterial disease.
Recent reports show a 1% to 3% annual incidence of nonfatal MPll,128 The Edinburgh Artery
study has shown that patients with IC have a significantly increased risk of angina (relative risk,
2.31) whereas asymptomatic PAD patients have a slightly increased risk ofMI and stroke.I-?
The frequency of these events seems to be correlated with PAD severity, as assessed by ABPI or
the presence of popliteal trifurcation disease, 111,138 Indeed, Ogren et al1l8 found that an ABPI
less than 0.9 was the best predictor of stroke in 68-year-old men with asymptomatic carotid
stenosis. Table 3 summarizes the limited information about the incidence of nonfatal cardiovas-
cular events in patients with Ie. There seems to be general agreement that between 2% and 4%
of patients with IC have a nonfatal cardiovascular event within the first year.
A 2.5.1 Mortality
In the 1950s, Allen et a[142 stated that half of the existing patients with IC would be dead with-
in 5 years, and Stammersl<' added that those aged 55 to 60 years would die of CAD within 5
Table 3: The incidence of nonfatal cardiovascular events in patients with intermittent claudication
Study No ofpatients
Bloor, 196P2S 1,476
Begg & Richards, 1962 ]04 198
Peabody et al, 1974 139 162
Kallero ct al, 1985 138 368
Widmer ct al, 1986 140 236
Gilliland et al, 1986 128 400
Dorrnandy & Murray, 1991111 1,969
Davey Smith et al, 199114] 18,403
Leng et al, 1996137 1,592
CAPlUE, 199662 19,185
Pollow-up (yrs)
5
5-13
18
0.1-11
11
5.5
5
1-3
Nonfatal cardiovascular events (%)
20
28.7
Cardiac: 44 men; 34 women
cerebral: 4 men; 3 women
Cardiac: 6.5
cerebral: 7.9
Cardiac: 15.5 cerebral: 12.4
Cardiac: 14
cerebral: 5
Cardiac: 1.2
cerebral: 1
Possible MI: 20.1
angina: 16.5
Ml: 8.2
angina: 9.6
CVD: 6.8
Ml: 2.9
CVD: 5.3
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Figure 12: Survival of patients with intermittent claudication and matched controls.
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years . Although these opinions now seem overly pessimistic, they show an appreciation of the
higher mortality rate of patients with symptomatic PAD. Bloor125 estimated that a claudicarit's
life expectancy was decreased by 10 years. Despite disparity in patient selection, over two doz en
studies show some degree of agreement about the overall mortality in those with IC. The 5-)
10-, and IS-year mortality rates from all causes are approximately 30%, 50%, and 70%, respec-
tively-an outlook that is not much better than that following resection of a Duke's B carcino-
ma of the colon . This emp hasizes most clearly that the real danger for the patient with symp-
toms of leg ischemia, intermittent claudication, is not losing the leg but rather suffering prem a-
ture cardiovascular complications or death. Both patie nts and their physicians should th erefore
give th erapeutic priority to the latte r.
The Coronary Artery Surgery Study (CASS) compared survival in 2,296 patients with PAD and
13 ,9 53 controls. Patients with PAD were found to have a 25% greater likelihood of dying com-
pared with those without (hazard ratio, 1.25) .144 ABPI has also been correlated with mortality
in two studies.6,145 In the first study, with 1,492 women older than 65 years, the 4-year mortal-
ity rate in those with an ABPI greater than 0.9 was 9 .5%, compared with 53 .7% in those with an
ABPI of 0 .9 or less.s Similar results were found in the second study, in 1,537 men and women
older than 60 years, which found mortality rates after 1 to 2 years' follow-up of 1.7% in those
with an ABPI greater than 0.9 and 6.9% in those with an ABPI of 0.9 or lcss.145
Of particular interest are the studies in which the difference in mortality rates between claudi-
cant and no nclaud icant patients was adjusted for differences in known risk factors such as smok-
ing, hyperlipidemia, and hypertension. Such risk factors would be expected to be commoner in
and contribute to a higher mortality rate in patients with IC . The increased risk of dea th in
c1audicant patients was largely unchanged despite the adjustment for risk factors. These surpris -
ing but consistent results suggest that there may be a special, as yet unidentifiable, risk factor in
patients with IC other than simply atherosclerosis. Figure 12 pools the results from all studies
comparing mortality rates of c1audicant patients with those of a matched nonc1audicating popu-
lation . As expec ted, the two lines diverge steadi ly at a constant slope, indicating that on average
th e mortality rate of claudicant patients is 2.5 times that of non claudicant patients.
A 2 .5 .2 Cause of Death in P atients With Intermittent Claudication
Although CAD is by tar the most common cause of death among patients with PAD, the pro-
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Figure 13: Cause of death in patients with Ie and in the general population in Germany in 1996
(source: Federal Statistical Office of Germany).
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portion is still surprisingly low (40%-60%), with CVD accounting for 10% to 20% of deaths.
Other vascular events, mostly ruptured aortic aneurysm, account for approximately 10%. Thus,
20% to 30% of patients with PAD die of noncardiovascular causes (Figure 13).
A 2.5.3 Swnmary: Fate of the Claudicant
Figure 14 summarizes the fate of the claudicant, which is relatively benign as regards local dis-
ease in the leg, but which is increasingly malignant in terms of fatal and nonfatal serious cardio-
vascular events. Only approximately 5% of patients with IC need surgical or endovascular inter-
vention over 5" years for either severe claudication or deterioration to critical limb ischemia.
Approximately 2% of patients with Ie ever need a major amputation.
A 2.5.4 Risk Factors for Systemic Morbidity or Mortality
Not surprisingly, the presence or absence of severe CAD seems to determine a claudicant's fate.
Dormandy and Murray found that patients with IC and CAD wen: twice as likely to die as those
without CAD.l11 Both Begg and Richards104 and Juergens et all30 noted that claudicant
patients with clinical or electrocardiograph evidence of coronary ischemia had survival curves
similar to those who had survived an MI.
Because low ABPI «0.5) has been shown to be related to the severity of CAD, it is not surprising
that this index has also been associated with an increased mortality risk.? McDermott et al146 have
shown mat the ABPI is a powerful tool for predicting survival i.n patients with PAD; patients with
an ABPI of 0.3 or less had a significantly poorer survival rate than those with an ABPI of 0.31 to
0.91 (relative risk, 1.8). A recent study has shown that, in multivariate analysis, hypertriglyc-
eridernia (~ rnmoly'L) was the only independent factor associated with deterioration ofAEPI (rel-
ative risk, 1.8) and with me onset ofCLl (relative risk, 1.9).78 Smoking147,148,149 dia-
betes,105,106,107,108,109,111,126,147 hypertension,104,111,126 white cell count,111,148 asymptomatic
carotid disease,150 and fibrinogen 148,151 have all been reported as predictors ofmortality. Smoking
increases mortality rates among patients with IC by between 1.5 and 3.0. 5 Figure 15 illustrates the
odds ratios for different risk factors; it is interesting that diabetes and smoking seem to be less of a
risk for total mortality than tor progression of local disease in the legs (see Figure 11). The ABPI
seems to be a far better predictor of all-cause mortality in these patients.
A2.6 Critical Limb Ischemia
Critical limb ischemia (Cl.I] i.s the term used to delineate those patients whose arterial disease
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Figure 14: Five-year tate of the claudicant.
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has resulted in a breakdown of the skin (ulcer or gangrene) or pain in the foot even at rest, It
therefore coincides with stages III and IV of the Fontaine classification, This equates to the
Rutherford 4, 5, and 6 categories of the New SVS-ISCVS Recommendation of Reporting
Standards.ls- The principal reason for adopting this broad inclusive definition is that most of
the epidemiological data relate to this whole group. It is not possible to talk about the natural
progression of these patients because they inevitably require active intervention. Although
numerically far less than patients with IC, patients with CLI demand a disproportionately large
commitment both in medical effort and economically. They also represent the major workload
for vascular surgical units. However, it is only much more recently that data have been collected
on large series of CLI patients outside the context of specific surgical procedures.
A 2.6.1 Incidence and Prevalence of eLI
There is little direct information on the incidence of CLI. Catalano l53 assessed its incidence in
North Italy using three different approaches. First, a prospective 7-year study on the incidence
ofCLl in 200 patients with IC and 190 controls (development); second, a prospective S-monrh
study of hospitalizations for CLI in a sample of hospitals in Lombardy (hospitalizations); and
third, encoding the major amputations performed in the hospitals in two regions (Lombardy for
6 months, Emilia Romagna for 2 years) (major amputations). The results from the three
approaches were substantially equivalent in order of magnitude (Table 4).
Table 4: Incidence of eLI and major amputations in the population aged >45 years in Northern Italy
using three different approacheslff
Incidence of cu
(per millionpel'year)
Incidence of major amputations
(per millionper year)
Development of Cl.I
Hospitalizations for CLI
Major arnputations
Lombardv
Emilia Rornagna
450
652
577
530
112
160
172
154
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Figure 15: Range of odds ratios (univariate) for risk factors for all-cause mortality.
Protective
-2 1
! !
Odds ratio
Harmful
2 3
, ,
4
1
Male gender (cf female)
Age (per 10 years)
ASPI «0.5 to >0.8)
Diabetes
Smoking
Hypertension
CAD • I
Based on a national survey, the Vascular Surgical Society of Great Britain and Ireland concluded
that there Were 20,000 patients with CLI in the population, an annual incidence of 400 per mil-
lion per year,154 The incidence of CLI can also be extrapolated from the better-documented
prevalence studies of I'C. If one assumes that the overall prevalence of claudication is 3% and
that 5% of patients with IC will develop CLI over 5 years, this gives an incidence of eLI of 300
per million per year. Finally, the incidence of CLI can be calculated from the number of major
amputations performed (Table 6). Assuming that 90% of major amputations are performed for
ischemia and that only 25% of patients with CLI ever require a major amputation, it can be cal-
culated that the incidence of CLI is approximately 500 to 1,000 per million per year.
Surprisingly perhaps, the incidences calculated using these different methodologies are very sim-
ilar. Roughly, one new patient per year will develop CLI for every 100 patients with Ie in the
population.
A 2.6.2 Risks Factors for the Development of Critical Limb Ischemia
The risk factors for the development of CLI are exactly the same as those for the progression of
local disease, the most important, apart from age, being smoking and diabetes.
Age
As already stated, the prevalence of PAD increases rapicUy with age, as does the hospital admis-
sions rate.57 Major amputations are also more common in the elderly. In a 3-year prospective
study oflower limb major amputations in Malmohus county in Sweden, 45% of the amputees
were at least 80 years 01d.I55 In a Danish national discharge survey in 1980, the incidence of
lower limb major amputations increased from 0.3 per 100,000 per year for those younger than
40 years, to 226 per 100,000 per year for those older than 80 years.156
Smoking
Cigarette smoking increases both the risk of developing PAD and its progression. The risks asso-
ciated with smoking apply to all ages and increase with the number of cigarettes smoked.U? In
multivariate analyses, smoking has been shown to be an independent risk factor64,94,155 and to
be more important in causing PAD than CAD.94 Major amputation is more common among
patients with IC who are heavy srnokerslf? and who continue to smoke.U?
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Diabetes
Diabetes mellitus affects 2% to 5% of Western populations. However, 40% to 45% of all
amputees are diabetic. Therefore, diabetic PAD patients are approximately 10 times more likely
to need an amputation than nondiabetic PAD patients. The Basle stue\.y repartee\. that ma)or
amputations were 11 times more frequent in diabetic PAD patients than in nonc\.iabeticllAD
patients.Pt One study reported the progression of eLl to gangrene to be 4Cl% in diabetic
patients compared with 9% in nondiabetic patients.56 The correlation between c\.iabetes an<.\
major amputation rates is independent of other risk factors, indu<.\ing age and. smo\ti.ng.l 56,
However, smoking does appear to have an additive effect.l 58 Those with diabetes generally
undergo major amputations at an earlier age than those without diabetes.l59,16D,161
A 2.7 Fate of Patients With Critical Limb Ischemia
It is no longer possible to describe the natural history of the critically ischemic limb, because
most patients now undergo some form of arterial reopening procedure. Table Sa shows the
mortality rates in some large series of patients, most of whom newly presented with CLI to a
vascular surgical center. It is interesting to note the variation in the proportion ofpatients where
some form of revascularization was attempted. In some highly specialized and aggressive units,
90% or more of the patients had an attempted revascularization. The primary amputation rate
varied from approximately 10% to approximately 40%. The remaining patients had general sup-
portive and medical treatment only. The studies in Table Sa are mostly from single centers.
Perhaps a better picture of what happens to an average patient who develops CLI would come
from multicenter audit data. Some examples of these are shown in Table 5b.
More recently, several studies have reported the fate of patients with recently diagnosed CLl
after 1- and 2-years' follow-up. Wolfel62 in Britain has reported 'l-ycar mortality rates of around
20% in unselected patients with CLI, while a study in Zurich found a similar proportion dying
over 6 months. 163 In a prospective observational study in Italy, 574 patients were recruited in
69 centers mainly on the basis of clinical findings of CLI (rest pain and/or trophic lesions). At
the end of three months, 50 (8.7%) patients had died, 3 (0.5%) had an MI, 6 (1.0%) a stroke,
70 (12.2%) a major amputation, while 103 (17.9%) had persistent CLI. In a subsequent follow-
up report 21.9% (121/552) were dead at 1 year, while an additional 44 (11%) died during the
second year, giving an overall 2-year mortality of 31.6%.164As expected, the overall incidence of
vascular deaths was much higher than that for non-vascular deaths (34.5 vs 8.5%, respectively).
Cardiovascular deaths were also relatively higher at the end of the first (36.4 vs 6.6% respective-
ly) than at the end of the second (29.5 vs 13.6%, respectively) year of follow-up.lvt
Finally, there are some good-quality data from multicenter, closely monitored trials of pharma-
cotherapy for CLI. These are summarized in Table 5c. Unfortunately, these data only relate to a
subgroup of patients who are completely unreconstructable or in whom attempts at reconstruc-
tion have failed. It is only such patients who are entered into randomized, placebo-controlled
clinical pharmacotherapy trials. Information about the spontaneous course of CLI can therefore
be deduced from those patients who receive placebo. The results for this subgroup reveal the
appalling prospect that approximately 40% will lose their leg within 6 months, whereas up to
20% will die. 176,177,178,179 In most of these studies, less than half of the patients were alive with-
out a major amputation after 6 montlls. 177,l78,179 De Weese and RoblDS found that virtually all
(95%) patients who presented with ischemic gangrene and 80% of those presenting with rest
pain were dead within 10 years.
A2.8 Changing Outcome of Critical Limb Ischemia
There is an ongoing controversy, often fueled by unverified retrospective audit data from large
and changing populations, as to whether there is a significant reduction in amputations as a
result of more vascular reopening procedures in patients with CLI.l8D,181 A recent, particularly
careful, study of a fixed population in Sweden over 8 years strongly suggests that a decrease in
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Table 5: Fate of patients with critical limb ischemia
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No ptuients/
limbs
Attempted
re-vascular-
ization (%)
Primary
ampumtion
(%)
Follow-up Mortality
(yrs) rate (%)
Alive
with
persistent
eLI
Alive
without
nniputntion
(%)
Ampu-
tation
(%)
a) S1JI:giea! series
McGrath ct ai, 1;;7 1983 2,064 22.6 4.2
Ouriel er al, 11>5 1988 362 56.3 43.6 1 71..,
Griffith and Cll1um,166 1988 402 67.1 36.~ 2 50
2~
Holdsworth, I1>7 1997 319 43 18 12 (amp) 51
8 (revasc)
Veith ct al,II>R 1981 755 89.9 10 5 52
Taylor cr al,l09 1991 627 97.2 2.8 1.95 2.3 7.0
Hickey cr "I, 20<) 199 1 315 88 14.2 5 41
b) Multicenter series
Wolfe, 11>2 1986 409 61 7 1 18 26
tcxr Group,l64 1997 522 44.4 9.4 2 31.6 55 13.8 13.8
e) Unreconstructnblc or primnry failed reconstruction
Tonnenscn er 011,170 197R 21 19
Lowe ct ,II,L76 1982 13 30.7 l ' 6 mo 23-;>
Belch er al,l77 1983 13 7.69 61110 23 53.8 l5.4
Schuler ct al,171 1984 63 9.52 14.2 2 mo 4.7 14.3
Telles et al,l72 1984 17 29.4 1 rno 29.4
Norgren er al,l78 1990 52 44.2 61110 31 43.4
Bliss ct 011,17<) 199] 71 6 rno 11 42 46.4
Balzer ct al,173 1991 58 11110
Guilmor & Dior,17-1 1991 41 3 19.5
Lepantalo & Matzke,175 1996 105 (136) 12 54 19.5
primary amputation (from 42% to 27%), associated with a corresponding increase in revascular-
izations, resulted in an overall decrease in amputations from 61 % to 47%.182 In the United
Kingdom, the number of major amputations has reached a plateau, possibly reflecting increas-
ingly successful limb salvage_183 A decline in major amputation rate has also been reported in
Denmark: from 34.5/100,000 in 1983 to 25/100,000 in 1990. 184 Between 1981 and 1990 in
Scotland, the major amputation rate fell by 22%.185 However, this study highlighted inconsis-
tencies within different age-sex groups. Thus, in the population younger than 65 years, the
major amputation rate decreased by 45%, whereas in those older than 65 years, it increased by
54%.
Major amputation rates also decreased in men, but there WJ.S a paradoxical increase in women.
During the period of this study, the reduction in major amputation rate was accompanied by a
doubling of the ra.te of arterial reconstructions, with an increase in all age-sex groups. In
Western Finland, Luther reported a 22-year (1970-1991) retrospective survey of surgical
patient data compared with population data, which showed a 2.S-fold increase in major amputa-
tions from 1970 to 199 L 186 Figure 16 summarizes in diagram form the initial overall treatment
of all patients presenting with CLI, and Figure 17 summarizes the data from studies looking
only at "end-stage" CLI, those patients who are unsuitable for revascularization or in whom
revascularization has failed and cannot be repeated (Table 5c).
Allowing for the different periods of follow-up, it is surprising that the fate of the patients with
eLI who have just presented and are considered for primary reconstruction is not much better
than that of patients in whom reconstruction is impossible or has failed,
A2.9
A 2.9.1
Major Amputation
Incidence and Prevalence of Major Amputation
The concept of patients who have a poor outcome, steadily progressing through increasingly
severe claudication to rest pain, ulcers, and ultimately amputation, is incorrect. As already point-
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Figure 16: The tate of patients with CLI.
Figure 17: Outcome at 6 months in patients who were either unsuitable for, or who failed, revascularization.
cd out, an acute onset of CLI carries a particularly bad prognosis. In a recent study, it was
found that more than halfof713 patients having a below-knee major amputation for ischemic
disease had no symptoms ofleg ischemia as recently as 6 months previously.Je? In 1986 in
England and Wales, nearly 5,000 new patients were referred for prosthesis fitting after major
amputations tor CLI.188 There are no accurate data on the number of patients in the United
Kingdom undergoing major amputation without referral for a prosthesis but, using the figures
available tor progression of claudication, total major amputations may be in excess of 15,000 per
annum (300 per million per annum).189 This compares with estimates of SOD/million popula-
tion/annum in Sweden.t''? 2S0/million/annum in Denmark,184 and 280/million/annum in
the United States 191 (Table 6). In Holland, Hoogendooru'v- has reported on the major ampu-
tation rate according to the level of major amputation.
A 2.9.2 Risk Factors for Major Amputation
Although not substantiated by an adequate prospective study, the presence of gangrene and
ulceration (Fontaine IV), but not necessarily the size or number of ulcers, seems to be associat-
ed with a poorer prognosis than rest pain alone (Fontaine III).193 In the Joint Vascular Research
Group in Britain study,162 patients with ell who had gangrene or ulceration were twice as like-
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Table 6: Estimated number of major amputations/annum in different countries
Estimated number/nullion/nununi
Dorrnandy & Ray, 1996189
Norgren , 1990l l) ()
Ebskov et al, 1994184
Kacv er nl, 1982 1'11
Hoogendooru, l'J81l 1'12
Pcll ct aI, 199418;
Luther, 19941Sf>
UK
Sweden
Denmark
USA
Holland
Scotland
Wcsrcrn Finland
300
500
250
280
2~6
142
120
ly to require a major amputation as those with rest pain alone. Juergens er al130 noted a 5-fold
increase in a similar group OVera 5-year period. Several studies have shown that survival without
amputation in eLI patients is related to ABPI.146 ,194,195 This is not surprising; ABPI has already
been shown to be one of the most accurate predictors of mortality in daudicant patients (sec
also A 3 .2.3, Criteria tor Success, P S36).I11 The precise magnitude of the effect and whether it
is similar in patients with rest pain alone and those who also have trophic changes has been
much debated. The Joint Vascular Research Group in Britain162 tound that there were signifi-
cantly (p < 0.01 ) more viable legs at 1 year among those patients with eLl who had rest pain
(Fontaine III) and an ankle pressure greater than 40 111m Hg compared with those with rest
pain and an ankle pressure less than 40 111m Hg. This differentiation, however, was lost in those
patients with ulceration or gangrene (Fontaine IV) . It was therefore concluded that although
ankle pressure was a predictor in eLl patients with rest pain alone, it was oflittk additional
value in those patients with ulceration and gangrene.
Level of ampHtation
A review of 16 reports over the last 30 years shows that the ratio of below-knee (BK) to above-
knee (AK) amputation is usually near 1 and has not changed over the
years. 196,197,198,199,200,201 ,202,203,204,205,206,207,208,209,210,211 A more accurate picture of the
changing pattern of amputation may be obtained by looking at longitudinal studies from the
same center, In one series, the introduction of an aggressive team approach to amputation
increased the BK-to-AKratio from an unusually low 0.14 to 2.1. 198 Data from published series
looking at the delayed healing and revision rates for BK amputations show that primary healing
ranged from 30% to 92% (m ean, 70% to 75%)187,/97,198,203,204,205,212,213,214 and the re-amputa-
tion rate from 4% to 30% (mean, 15%).208,210,211,215,216,217,218 Approximately another 15% had
delayed or secondary healing, which, in some cases, required debridement and further proce-
dures such as wedge excision in an attempt to maintain leg !ength.219,220,221,222,223 Of the 30%
of B K amputees whose wounds do not heal primarily, approximately half will need a higher
major amplitation.224,225,226,227.22S Less blood flow is required to keep tissues healed than to
achieve healing, and Kihn et al197 reported that once a BK major amputation healed, only 4% of
such patients ever require a higher amputation .
Data from 51 hospitals in six European coun tries were collected regarding 713 patients requir-
ing a BK amputation. 1S7 In this study, at 3 months , 59% ofstumps had healed, 19% required an
amputation at a higher level, and II % remained unhealed . The surgeons' assessment of the like-
lihood of healing was wrong in 21% of cases in which the operating surgeon believed that heal-
ing would occur. It was also wrong in 52% of cases in which it WaS thought that healing would
not occur. Similarly, it is generally believed that increasing the proportion ofBK to AK amputa-
tions must inevita bly lead ro a higher failure rate. Neither of these beliefs is borne out by com-
parative. studies of the literature.
A 2.9.3 Fate of the Arnpurec
Two to three times as many RIC amputees achieve fulll110bility compared with AK amputees,
and there has not been any dramatic change in 20 year5. 196,199,205,215,217 Initial rehabilitation
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may take up to 9 months, but by 2 years, 30% of amputees arc not using their prostheses.196
Older pati ents, wo men, and bilateral amputees arc particularly bad ar mobilizing. 196,225 Kihn ct
ajl 96 noted that onl y 25% of amputees had palpable toot pulses in the contralateral limb and
that, over a 2- year period, approximately 15% required contralateral major arnputario n.
Although the need for major amputation was related to the absence of distal pulses, 10% of the
amputees with palpable contralateral foot pulses also lost that foot within 2 years . Early hospital
mortality rate s afte r BK amputation range in most se ries from 3% to 10%, whereas the hospital
mortality after an AK amputation is nearer 20%.196,198,20 1,202,203,205,207,212,215,217,224,228,229 It is
unlikely that this increased mortality rate is directly due to the higher level of amputation.
Rather, it is due to the selection of the older and "high-risk" patients, who have little prospect
of rehabilitation, for what is considered a more reliable procedure in terms of primary healing,
and the fact that they have more widespread art erial disease. However, several reports have relat-
ed operative mortality to coexisting medical conditions, such as diabetes and cardiovascular,
cerebrovascular, and respiratory disease and found no significant correlation. 196,208 This differ-
ence is maintained for up to 2 years, wh en mortality rates of 25% to 35% tor BK an d 45 % for
AK amputees are seen .190,19:i ,1 98,21 5
A 2.9.4 Summary: Major Amputation
Figure 18 summarizes the tate of the BK amputee . Five years after a BK ampu tatio n , 30% will
have had a major contralateral amputation, 50% will be dead, and only 20% will be alive with
one intact leg.
The nature of the on set of CLI may also be imp ortant. Between 30% a nd 70% of patients who
develop acute eLI require major primary am pu tation, possibly becau se th ey tend not to be
tre ated in specia list cente rs, and becau se patients with acute CLI will not have had the opportu -
nity to develop coll nrerals.P"
A 2.10 Conclusions
There are st ill surpri singly little good epidemiological data on PAD co m pared with CAD or
CVD. It is, however, clear that the prevalence of symptomatic and asymptomatic PAD is greater
than previously thought- Both groups carry a high risk of death or morbidity because of vascular
Figure 18: Early and 2-year fate of the below-knee amputee (from normandy & Ray).
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disease in other territories, eLI is much rarer but carries an even worse prognosis, in terms of
both morbidity and mortality, which is comparable to some of the most malignant cancers. The
current treatment modalities, in terms of either preventing progression of local disease in the
legs or modifying the high mortality, are not particularly successful.
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